Royalty Pharma (RPRX) Citi Annual Global Healthcare Conference 2025 summary

Strategic initiatives and capital allocation

• Internalized external management, consolidating operations for strategic and financial benefits.

• Authorized a $3 billion share repurchase, executing $1 billion in buybacks in the first half of the year, with activity slowing as deal flow increased.

• Capital allocation is guided by relative stock value and attractiveness of royalty opportunities, shifting focus as market conditions evolve.

• Deal flow momentum remains strong, with notable transactions like Revolution Medicines and Imdeltra.

• Baseline capital deployment is $2–2.5 billion annually, with potential for higher levels driven by industry innovation and partnerships.

Deal structuring and market trends

• Increasing demand for customized and creative deal structures, including evolving royalty agreements and milestone-based payments.

• Partnerships with pharma for R&D funding are expected to grow, offering attractive risk-sharing models.

• Competition from new entrants like Blackstone is viewed positively, expanding the royalty market and increasing legitimacy.

• AI is being integrated into diligence and analytics, but core barriers to entry remain capital, scale, and experience.

Investment approach and risk management

• Focus remains on internal rate of return, with new metrics introduced: return on invested capital (mid-teens) and return on equity (low 20%).

• Returns are expected to be sustainable without taking on additional risk, maintaining a balanced portfolio across approved and development-stage assets.

• Equity investments are used selectively as a supplement to royalty deals, not as a core strategy.

• Broad investment across therapeutic areas mitigates risk and ensures portfolio renewal.